{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:56Z","timestamp":1761562496984,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41397-019-0087-z","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T23:07:30Z","timestamp":1554851250000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer"],"prefix":"10.1038","volume":"20","author":[{"given":"Harriet","family":"Johansson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Aristarco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Macis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliana","family":"Guerrieri-Gonzaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-4002","authenticated-orcid":false,"given":"Matteo","family":"Lazzeroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnita","family":"Rajasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark V","family":"Williard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"DeCensi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"87_CR1","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G, Ornati G, Di SE, Lonning PE, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998;4:2089\u201393.","journal-title":"Clin Cancer Res"},{"key":"87_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/FPC.0b013e32833b04af","volume":"20","author":"D Sun","year":"2010","unstructured":"Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics. 2010;20:575\u201385.","journal-title":"Pharmacogenet Genomics"},{"key":"87_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ygeno.2004.06.011","volume":"84","author":"W Wilson III","year":"2004","unstructured":"Wilson W III, Pardo-Manuel D,V, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics. 2004;84:707\u201314.","journal-title":"Genomics"},{"key":"87_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnci\/djh167","volume":"96","author":"AM Dunning","year":"2004","unstructured":"Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst. 2004;96:936\u201345.","journal-title":"J Natl Cancer Inst"},{"key":"87_CR5","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-06-4123","volume":"67","author":"CA Haiman","year":"2007","unstructured":"Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007;67:1893\u20137.","journal-title":"Cancer Res"},{"key":"87_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1055-9965.EPI-03-0026","volume":"13","author":"SS Tworoger","year":"2004","unstructured":"Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13:94\u2013101.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"87_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/0008-5472.CAN-09-3224","volume":"70","author":"L Wang","year":"2010","unstructured":"Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010;70:319\u201328.","journal-title":"Cancer Res"},{"key":"87_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0373-9","volume":"13","author":"O Artigalas","year":"2015","unstructured":"Artigalas O, Vanni T, Hutz MH, shton-Prolla P, Schwartz IV. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis. BMC Med. 2015;13:139.","journal-title":"BMC Med"},{"key":"87_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ng.586","volume":"42","author":"C Turnbull","year":"2010","unstructured":"Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010;42:504\u20137.","journal-title":"Nat Genet"},{"key":"87_CR10","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.12659\/MSM.894010","volume":"21","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhang M, Yuan X, Zhang Z, Zhang P, Chao H, et al. Association between ESR1 PvuII, XbaI, and P325P polymorphisms and breast cancer susceptibility: a meta-analysis. Med Sci Monit. 2015;21:2986\u201396.","journal-title":"Med Sci Monit"},{"key":"87_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/ng.318","volume":"41","author":"W Zheng","year":"2009","unstructured":"Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009;41:324\u20138.","journal-title":"Nat Genet"},{"key":"87_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/01.CIR.0000016173.98826.88","volume":"105","author":"DM Herrington","year":"2002","unstructured":"Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879\u201382.","journal-title":"Circulation"},{"key":"87_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s10552-005-0307-5","volume":"16","author":"NC Onland-Moret","year":"2005","unstructured":"Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH. The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control. 2005;16:1195\u2013202.","journal-title":"Cancer Causes Control"},{"key":"87_CR14","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1158\/1078-0432.CCR-09-3092","volume":"16","author":"SL Ding","year":"2010","unstructured":"Ding SL, Yu JC, Chen ST, Hsu GC, Hsu HM, Ho JY, et al. Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res. 2010;16:3473\u201384.","journal-title":"Clin Cancer Res"},{"key":"87_CR15","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.7314\/APJCP.2012.13.10.5105","volume":"13","author":"LW Li","year":"2012","unstructured":"Li LW, Xu L. Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:5105\u201311.","journal-title":"Asian Pac J Cancer Prev"},{"key":"87_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/1940-6207.CAPR-15-0311","volume":"9","author":"V Aristarco","year":"2016","unstructured":"Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, et al. A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients. Cancer Prev Res. 2016;9:349\u201356.","journal-title":"Cancer Prev Res"},{"key":"87_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/03602530903208652","volume":"42","author":"P Lazarus","year":"2010","unstructured":"Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev. 2010;42:182\u201394.","journal-title":"Drug Metab Rev"},{"key":"87_CR18","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","volume":"30","author":"EJ Folkerd","year":"2012","unstructured":"Folkerd EJ, Dixon JM, Renshaw L, A\u2019Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30:2977\u201380.","journal-title":"J Clin Oncol"},{"key":"87_CR19","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1210\/jc.2007-0359","volume":"92","author":"C Swanson","year":"2007","unstructured":"Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, et al. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab. 2007;92:4878\u201382.","journal-title":"J Clin Endocrinol Metab"},{"key":"87_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ajhg.2008.10.006","volume":"83","author":"TL Yang","year":"2008","unstructured":"Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet. 2008;83:663\u201374.","journal-title":"Am J Hum Genet"},{"key":"87_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00198-011-1662-6","volume":"23","author":"S Giroux","year":"2012","unstructured":"Giroux S, Bussieres J, Bureau A, Rousseau F. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women. Osteoporos Int. 2012;23:1163\u201370.","journal-title":"Osteoporos Int"},{"key":"87_CR22","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.1007\/s11033-012-1938-8","volume":"39","author":"E Eskandari-Nasab","year":"2012","unstructured":"Eskandari-Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, Moghaddam SS, et al. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 2012;39:10531\u20139.","journal-title":"Mol Biol Rep"},{"key":"87_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/MED.0000000000000411","volume":"25","author":"YX Chan","year":"2018","unstructured":"Chan YX, Yeap BB. Dihydrotestosterone and cancer risk. Curr Opin Endocrinol Diabetes Obes. 2018;25:209\u201317.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"87_CR24","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-05-3984","volume":"66","author":"LF Macedo","year":"2006","unstructured":"Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66:7775\u201382.","journal-title":"Cancer Res"},{"key":"87_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2505-2","volume":"139","author":"C Campagnoli","year":"2013","unstructured":"Campagnoli C, Pasanisi P, Castellano I, Abba C, Brucato T, Berrino F. Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Res Treat. 2013;139:1\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"87_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1055-9965.EPI-15-0324","volume":"24","author":"DS Chan","year":"2015","unstructured":"Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev. 2015;24:1439\u201349.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"87_CR27","doi-asserted-by":"publisher","first-page":"e0177137","DOI":"10.1371\/journal.pone.0177137","volume":"12","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS ONE. 2017;12:e0177137.","journal-title":"PLoS ONE"},{"key":"87_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fphar.2017.00218","volume":"8","author":"DM Glubb","year":"2017","unstructured":"Glubb DM, O\u2019Mara TA, Shamsani J, Spurdle AB. The association of CYP19A1 variation with circulating estradiol and aromatase inhibitor outcome: can CYP19A1 variants be used to predict treatment efficacy? Front Pharmacol. 2017;8:218.","journal-title":"Front Pharmacol"},{"key":"87_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-007-9822-2","volume":"112","author":"PA Fasching","year":"2008","unstructured":"Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2\/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat. 2008;112:89\u201398.","journal-title":"Breast Cancer Res Treat"},{"key":"87_CR30","first-page":"5309","volume":"8","author":"X Shao","year":"2015","unstructured":"Shao X, Cai J, Zheng Y, Wang J, Feng J, Huang Y, et al. Rs4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. Int J Clin Exp Pathol. 2015;8:5309\u201317.","journal-title":"Int J Clin Exp Pathol"},{"key":"87_CR31","doi-asserted-by":"publisher","first-page":"18973","DOI":"10.3390\/ijms140918973","volume":"14","author":"L Liu","year":"2013","unstructured":"Liu L, Bai YX, Zhou JH, Sun XW, Sui H, Zhang WJ, et al. A polymorphism at the 3\u2019-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma. Int J Mol Sci. 2013;14:18973\u201388.","journal-title":"Int J Mol Sci"},{"key":"87_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1078-0432.CCR-07-1923","volume":"14","author":"R Colomer","year":"2008","unstructured":"Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res. 2008;14:811\u20136.","journal-title":"Clin Cancer Res"},{"key":"87_CR33","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","volume":"101","author":"AD Althouse","year":"2016","unstructured":"Althouse AD. Adjust for multiple comparisons? It\u2019s not that simple. Ann Thorac Surg. 2016;101:1644\u20135.","journal-title":"Ann Thorac Surg"},{"key":"87_CR34","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/hmg\/ddg294","volume":"12","author":"CA Haiman","year":"2003","unstructured":"Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet. 2003;12:2679\u201392.","journal-title":"Hum Mol Genet"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0087-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0087-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0087-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:59:55Z","timestamp":1684616395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0087-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0087-z","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"14 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted at the IEO, European Institute of Oncology IRCCS, Milan, Italy and approved by the Institutional Review Board. Written informed consent was obtained for all patients enrolled in the trial. Consent to use collected blood samples was obtained prior to sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}